A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma (2271)Katsutoshi Oda, Hiroyuki Aburatani, Akira Nishijima et al.|Gynecologic Oncology|2023Cited by 0
Mutational Signature‐Based Biomarker for Phase <scp>II</scp> Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian CancerKatsutoshi Oda, Kosei Hasegawa, Kazuyoshi Kato et al.|Cancer Science|2026Cited by 0